In a significant development for cancer patients worldwide, BeiGene's TEVIMBRA (tislelizumab) has secured an important new indication, reinforcing its position as an emerging leader in the immuno-oncology space. This expansion marks another milestone in the rapidly evolving landscape of PD-1 inhibitor therapies. Breakthrough Approval Enhances TEVIMBRA's Clinical Profile Regulatory...